AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions
Introduction: Cervical dystonia (CD) is a neurologic movement disorder with potentially disabling effects and significant impact on quality of life of those affected. AbobotulinumtoxinA (aboBoNT-A) was initially approved for a dilution of 500 U/1 mL and subsequently for a dilution of 500 U/2 mL, pro...
Guardado en:
Autores principales: | Mark F. Lew, Robert A. Hauser, Stuart H. Isaacson, Daniel Truong, Atul T. Patel, Allison Brashear, William Ondo, Pascal Maisonobe, Khashayar Dashtipour, Laxman Bahroo, Stefan Wietek |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1b10f3346552463da42e87acfb171361 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Muscle Selection and Dosing in a Phase 3, Pivotal Study of AbobotulinumtoxinA Injection in Upper Limb Muscles in Children With Cerebral Palsy
por: Joyce Oleszek, et al.
Publicado: (2021) -
Physicochemical stability of human insulin 1 I.U./mL infusion solution in 50 mL polypropylene syringes
por: Mohr André, et al.
Publicado: (2021) -
Consenso chileno sobre Abobotulinumtoxina A (Dysport®): indicaciones, técnicas
por: Chaná-Cuevas,Pedro, et al.
Publicado: (2013) -
Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study
por: Kongsaengdao S, et al.
Publicado: (2018) -
EVALUATION OF TOXICITY OF INFUSION SOLUTION OF POTASSIUM AND MAGNESIUM ASPARAGINATE 500 ML IN EXPERIMENT
por: A. G. Yushkov, et al.
Publicado: (2012)